Clinical Trial

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

Study acronym: SPRINT
Recruiting
View on ClinicalTrials.gov →
Summary
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-07; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-04-29
Trial Details
NCT Number NCT07070765
Lead Sponsor University of Aberdeen
Collaborators: NHS Grampian
Conditions Breast Cancer
Enrollment 70 participants
Start Date 2025-12-12
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30